BridgeBio stockholders approve officer exculpation amendment and 5M-share increase in stock plan

BridgeBio Pharma, Inc.

Stockholders elected all five Class III director nominees: Kumar, Homcy, Dachille, Daniels, Lo.
Approved amendment to increase shares reserved under 2021 Stock Plan by 5,000,000 shares (128.9M for, 26.7M against).
Approved officer exculpation amendment to limit liability of certain officers as permitted under Delaware law (151.2M for, 5.6M against).
Ratified Deloitte & Touche as independent auditor for FY2025 (173.8M for, 56k against).
Non-binding advisory vote on executive compensation passed (117.6M for, 37.9M against, 1.2M abstain).

item 3.03item 5.07item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.